Acrivon Therapeutics, Inc. ACRV 深 沪
已收盘 02-06 16:00:00 美东时间
1.67
+0.070
+4.38%
华盛通- 最 高1.71
- 今 开1.61
- 成交量 61.98万股
- 最 低 1.61
- 昨 收 1.60
- 总市值 5269.71万
- 52周最高 6.08
- 市盈率 静 --
- 换手率 1.96%
- 52周最低 1.05
- 委 比 -12.24%
- 总股本 3155.51万
- 历史最高 25.47
- 量 比 1.01
- 振 幅 6.25%
- 历史最低 1.05
- 每 手 1
- 风险率 1.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Acrivon Therapeutics will present interim clinical data for ACR-368, a precision medicine targeting endometrial cancer, at the ESGO 27th Annual Congress in Copenhagen. Dr. Panagiotis Konstantinopoulos, a global KOL, will highlight the data from the Phase 2b study, showcasing the drug's potential in a high unmet need population. The presentation is scheduled for Feb 27, 2026. Acrivon's proprietary Generative Phosphoproteomics AP3 platform drives i...
01-23 13:11
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Market-Moving News for January 8th
ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Accelerates ACRV: 38% | Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial Clinical
01-08 20:35
Acrivon Therapeutics to Release New Cancer Drug Data on Jan. 8
Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics
01-06 20:34
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
Acrivon Therapeutics will host a conference call and webcast on January 8, 2026, at 8:30 a.m. ET to discuss clinical data and updates on their drug candidates ACR-368 and ACR-2316, as well as a new preclinical candidate, leveraging their AP3 platform for precision drug development.
01-06 12:30
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock rose 63.6% to $3.19 during W...
2025-12-24 20:05
Acrivon Therapeutics Said It Will Be Providing ACR-368 and ACR-2316 Clinical Data And Other Updates In January 2026
Topics will include:Updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study as well as an update on the additional recently initiated tumor biopsy-independent Phase 2b arm, and the
2025-12-17 20:35
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 price target.
2025-11-25 19:45
Acrivon Therapeutics Q3 EPS $(0.47) Beats $(0.61) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.61) by 22.57 percent. This is a 20.34 percent increase over losses of $(0.59) per share
2025-11-14 05:13
